Summary -

Key Takeaways Explained for a Non-Medical Audience

– Insulin resistance impairs glucose disposal in key tissues, prompting compensatory hyperinsulinemia in response.

– Hyperinsulinemia itself may precede and worsen insulin resistance by promoting metabolic dysfunction.

– Common consequences include hyperglycemia, hypertension, dyslipidemia, hyperuricemia, elevated inflammatory markers, endothelial dysfunction, and a prothrombotic state.

– Insulin resistance often develops 10 to 15 years before the clinical onset of type 2 diabetes.

– The condition contributes to metabolic syndrome, nonalcoholic fatty liver disease, and cardiovascular disease.

– Obesity—especially excess adiposity—is a primary acquired driver, though genetic predisposition also plays a role.

– Gold standard testing like the hyperinsulinemic‑euglycemic clamp is impractical; surrogate measures include HOMA‑IR, QUICKI, triglyceride‑to‑HDL ratio, and other indices.

– Insulin resistance increases risk for microvascular (neuropathy, retinopathy, nephropathy) and macrovascular (coronary, cerebrovascular, peripheral artery disease) complications.

– Lifestyle modification is the first-line intervention, emphasizing reduced caloric intake and avoidance of carbohydrates that drive excessive insulin demand.

– Physical activity enhances energy expenditure and improves insulin sensitivity in skeletal muscle.

– Medications may reduce insulin demand or improve insulin response, but are secondary to lifestyle.

– Interprofessional care coordination enhances management and reduces progression of complications.

– Early detection and proactive management are essential to prevent long-term metabolic and vascular damage.